Company intelligence / Profile preview

Shenyang Tonglian Group

Shenyang, Liaoning, Chinadnb.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Shenyang Tonglian Group operates as a large private enterprise group with significant activities in the R&D, production, and sales of pharmaceuticals—especially medical raw materials and intermediates. Its portfolio includes over fifty varieties such as Rifamycin, Erythromycin, Penicillin derivatives, Vitamin C, Carrimycin, Ciprofloxacin Hydrochloride/Lactate among others. The company serves both domestic Chinese and international markets.

Therapeutic areas: Metabolic DisordersInfectious Diseases
Modalities: Small molecules
Industry: Chemicals & Materials

Drug pipeline

1 asset

carrimycin

Phase 3

Indications: COVID-19, Bacterial infections

Beyond the preview

Go deeper on Shenyang Tonglian Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenyang Tonglian Group.

Explore the full profile